Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Dogwood Therapeutics, Inc. DWTX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Dogwood Therapeutics, Inc. (DWTX) is a Biotechnology company in the Healthcare sector, currently trading at $1.71. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: DWTX trades at a trailing Price-to-Earnings (P/E) of -0.9 (S&P 500 average ~25).

Net income is $34M (loss), growing at -84.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $162,604 against $75M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.76 (strong liquidity). Debt-to-assets is 0.2%. Total assets: $90M.

Analyst outlook: 1 / 1 analysts rate DWTX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

DWTX SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — DWTX

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
DWTX: +0%/yr revenue is, -84.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet DWTX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 2.76 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
DWTX: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 1 / 1 analysts rate DWTX as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.77-9.5
Volume704.83K
Avg Volume (30D)54.37K
Market Cap$3.27M
Beta (1Y)2.07
Share Statistics
EPS (TTM)-4.32
Shares Outstanding$8.22M
IPO Date2020-12-17
Employees12
CEOGregory Duncan
Financial Highlights & Ratios
EBITDA$-27.97M
Net Income$-34.26M
Operating Income$-27.97M
Total Cash$6.52M
Total Debt$162.6K
Net Debt$-6.36M
Total Assets$90.17M
Price / Earnings (P/E)-0.4
Analyst Forecast
Rating ConsensusBuy
Analysts Covering1
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS92829J2033

Price Chart

Track all markets on TradingView
DWTX
Dogwood Therapeutics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.77 52WK RANGE 9.50

People Also View

EDSA
EDSA
Edesa Biotech, Inc.
$5.36
+2.68%
 SNSE
SNSE
Sensei Biotherapeutics, Inc.
$29.21
+1.78%
 COCP
COCP
Cocrystal Pharma, Inc.
$1.54
+0.65%
 TRAW
TRAW
Traws Pharma, Inc.
$1.23
-22.64%
 CLRB
CLRB
Cellectar Biosciences, Inc.
$3.04
+3.05%
 BOLT
BOLT
Bolt Biotherapeutics, Inc.
$4.91
+3.59%
 IMNN
IMNN
Imunon, Inc.
$3.15
+1.61%
 EVGN
EVGN
Evogene Ltd.
$0.81
-1.10%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message